USPTO trademark

WUXITECAN-2

Awaiting publicationUSPTOWord markClass 1Class 5Class 40Class 42

"WUXITECAN-2" is a word mark owned by WuXi XDC Cayman Inc., filed at the USPTO on March 26, 2026. It is waiting to be published and covers classes 1, 5, 40 and 42.

View WuXi XDC Cayman Inc. portfolioGet this data via the API
Official USPTO record
WUXITECAN-2 trademark as filed
As filed with the USPTO
Status
Awaiting publication
Since October 29, 2026
Filed
March 26, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99726259
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
4 classes
Ownership

Who owns WUXITECAN-2

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

WuXi XDC Cayman Inc.

Grand Cayman, Cayman Islands

27 trademarks in the portfolioView company

Representative

Candice Reder

Ice Miller LLP

Goods and services

What the mark covers

The products and services WUXITECAN-2 is filed for, grouped by Nice class.

  • Active chemical ingredients for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical reagents, other than for medical or veterinary purpose; Biochemical catalysts; Biological preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Heterocyclic compounds; Chemical preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Antibody reagents used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes

  • antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations for inhibiting tumors; antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical products for the prevention and treatment of cancer; Biological preparations for the treatment of cancer; Biological preparations for use in cell cultures for medical purposes; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical purposes; Antibodies for medical purposes; Biologics in the nature of cells for the treatment of cancer

  • custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Custom manufacturing of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Manufacturing services for others in the field of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload antibody drug conjugates and intermediates thereof; Custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations, biomedical preparations, drug conjugates, anti-body drug conjugates, chemical reagents; Biomanufacturing for others of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals using biological organisms in the manufacturing process

  • Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Research and development services of new pharmaceutical products; Research and development of antibody-drug conjugates; Research and development of conjugated antibodies; Product development consulting in the field of pharmaceuticals, anti-bodies, conjugated antibodies, chemical reagents; Product development for others; Biomedical research services; Scientific research in the nature of conducting clinical trials for others in the field of new pharmaceutical development

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Approved for pub - principal register
  2. Assigned to examiner
  3. Teas/email correspondence entered
  4. Correspondence received in law office
  5. Teas response to office action received
  6. Notification of non-final action e-mailed
  7. Non-final action e-mailed
  8. Non-final action written
  9. Assigned to examiner
  10. New application office supplied data entered

2 earlier steps on the official record.

FAQ

About WUXITECAN-2

Who owns the trademark "WUXITECAN-2"?

The USPTO trademark "WUXITECAN-2" (application 99726259) is owned by WuXi XDC Cayman Inc.

What is the status of "WUXITECAN-2"?

Its status at the USPTO is: awaiting publication.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull WUXITECAN-2 and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d4d09-9546-74a9-a489-7f9394623d30
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d4d09-9546-74a9-a489-7f9394623d30",
  "object": "trademark",
  "mark_text": "WUXITECAN-2",
  "status": {
    "primary": "pending",
    "stage": "pending_publication"
  },
  "office_code": "US",
  "application_number": "99726259",
  "filing_date": "2026-03-26",
  "nice_classes": [
    1,
    5,
    40,
    42
  ],
  "owners": [
    {
      "name": "WuXi XDC Cayman Inc.",
      "entity_id": "ent_019eb71e-a007-716c-9dce-41f4f3f39787"
    }
  ]
}